Taffix® blocks the Omicron Variant of SARS-CoV-2 in addition to the Alpha (UK) and Beta (South African) and Delta Variants Tel Aviv , Israel January 19 2022 – Nasus Pharma, a privately held clinical-stage biopharmaceutical company developing a powder-based intranasal (PBI) product portfolio to address acute medical conditions and public...
Nasus Pharma Announces Data Demonstrating In Vitro Efficacy of Taffix® Intranasal Antiviral Spray Against SARS-CoV-2 British and South African Variants
TEL AVIV, Israel, April 21, 2021 /PRNewswire/ -- Nasus Pharma a privately held clinical-stage biopharmaceutical company developing a powder-based intranasal (PBI) product portfolio to address acute medical conditions and public health threats, today announced data from a collaborative in vitro study with the Central Virology Laboratory, Ministry of Health, Public...
Nasus Pharma says its Taffix intranasal HPMC significantly reduced SARS-CoV-2 infection in real world superspreader event
Israeli biopharma company Nasus Pharma says that it provided its Taffix intranasal hydroxypropyl methylcellulose (HPMC) powder to members of a synagogue for use during Rosh Hashana celebrations, and worshippers who used Taffix were infected with SARS-CoV-2 at one quarter the rate of those who did not use the nasal powder. The members of...
Nasus Pharma Announces Data Demonstrating Efficacy of TaffiX® Intranasal Antiviral Protection Against SARS-CoV-2
TEL AVIV, Israel, July 07, 2020 (GLOBE NEWSWIRE) -- Nasus Pharma, a privately held clinical-stage biopharmaceutical company developing a powder-based intranasal (PBI) product portfolio to address acute medical conditions and public health threats, today announced data from a preclinical collaboration with the University of Virginia School of Medicine that demonstrated...
Nasus Pharma Announces First Clinical Data Demonstrating Efficacy of Taffix™ Intranasal Antiviral Protection Against SARS-CoV-2 in Super Spread Event
TEL AVIV, Israel, Oct. 13, 2020 /PRNewswire/ -- Nasus Pharma a privately held clinical-stage biopharmaceutical company developing a powder-based intranasal (PBI) product portfolio to address acute medical conditions and public health threats, today announced data from a prospective clinical post marketing users survey demonstrating that Taffix™, the Company's innovative nasal powder inhaler that effectively...